Roche Diagnostics Roche has introduced new viral load monitoring assays, cobas HIV-1 and cobas HCV assays, for use on its fully automated molecular diagnostic systems, cobas 6800/8800. With these next generation viral load monitoring assays, clinicians can manage the treatment of patients infected with human immunodeficiency virus (HIV-1) or hepatitis C (HCV). The viral load portfolio on the cobas 6800/8800 systems will improve lab productivity and help deliver results for faster clinical decision-making.

Roland Diggelmann, COO of Roche Diagnostics said, “The cobas 6800/8800 systems represent the next generation of molecular diagnostic instruments that offer unparalleled performance, unmatched flexibility and absolute automation. By virtue of their design and clinical utility, the cobas HIV-1 and cobas HCV tests set new industry standards for viral load assays, delivering on Roche’s commitment to provide new diagnostic tools to advance the medical community understands about viral disease and improves the ability to treat patients.”

Available in medium and high throughput models, the cobas 6800/8800 systems offer advanced performance with next generation donor screening assays viral load monitoring, women’s health and microbiology testing. Based on Nobel-prize winning PCR technology, the systems are designed to

  • Deliver increased automation and throughput with shorter time to results
  • Provide users with greater flexibility to increase overall workflow efficiencies

These molecular systems are now available in all markets accepting the CE mark, but are not currently available in the U.S. It is also reported that the cobas HIV-1 and cobas HCV assays will be followed by the cobas CMV and cobas HBV assays, which will complete the primary portfolio of viral load monitoring assays for the cobas 6800/8800 systems.

Founded in 1896, Roche is the world’s largest biotech company and the world leader in in vitro diagnostics. The company’s wide range of state-of-the-art diagnostic tests and systems play a significant role in the groundbreaking area of integrated healthcare solutions and cover the evaluation, early detection, targeted screening and monitoring of disease. Roche’s line of chemistry analyzers includes the Roche Cobas Mira Plus, Roche Hitachi 911, Roche Cobas Mira Plus CC and Roche Cobas Mira S.